5 Burst results for "Brian Corny"
"brian corny" Discussed on Watch What Crappens
"Member I thought this chartered did well. I mean even Kevin didn't sack so congrats Kevin Thank you Pity so yeah so they got a tip. That's like sixteen thousand which is about fifteen hundred per person which is on the lower end cates cates. Not Happy she's like you know this was like this is not the tip I was expecting. You're hoping for I mean there were children generally requests. The boat was Santo. The boat was filled with smoke and Ashen cancelled the beach party emphasis on Ashton cancelling the beach party. So I guess I guess I can't really be surprised. Why am I the only one who's GonNa job anyone doing other work here? Where did that come from and are? They didn't really build that up. They ended up a little bit. That was getting tired of the lack of respect for Iraq but they. It's sort of wedged that in there. Yeah it just seemed to come out of nowhere like why am I can work from Kuwait so so Ashton is like who wants to flake the chain and Riley's like I'll be fake today. He's like good job Riley play. I'M GONNA keep saying flake until I get laugh. FUCKING radio So so now they dock docking docking. Docking were coming coming in. We're coming in. Oh God oh God the both coming in. It's going to help. We've done a good job. Kid did a great job. That was great. So so cats with Coordinators which is. Why are you so grumpy? I like that that's fun. She's leave at like five today. I had I don't have any time off to go on a date. I'm Brian who ask someone out on the same day date you give it to you. Business Days at least manner from Mars women are from Venus and I like it go of renaissance. She's not she's not really wrong and she's like but then again. Brian lives five five feet away from me. And I'm like I like him so I'll go but you're gonNA wear. I have nothing to wear. I've never seen this side of you. What is it an iron aside? Because that's new so so that yes. Oh so while Courtney's preparing to go reluctantly going to date. Tanner is simultaneously. Tenuously planning his big break up with Simone so yeah and he was like saying that he doesn't you know is doing this whole spiel about how he doesn't want people get get on his case when hits another girl at the club. You know what I'm saying. I don't want everyone yelling at me next time. I go up to an employee of restaurant rubbing my crotch all over all right. Yea I don't want people to get off of my business. Next time I go up to a pot of plans to make out with it thinking that it might be you know what I'm saying. Yeah I love the tanners acting like he could have been getting all this ass that he just wasn't. Yeah of Simone like Dude the only thing that touched you was employed to be there and she was trying really hard not to test you and actually like ran away from her post so she didn't have to be touched by you. Please get over yourself seriously. He like reminds me of. I don't know if you ever saw the Mary Katherine Gallagher. Movie with Molly Shannon There's worse it's like so good and totally totally underrated and like one of the best scenes is when the Shannon makes out with a tree. That is like tanner in real life. Though he like literally like he probably thinks like trees are like hot girls. Hey what's going on. I just wanted to know that I have an opt out policy so If you don't WanNa kiss me back say something not saying anything. I'm GonNa make you tree tree. Kevin is talking to his. I love the Galley. He's like I'm feeling good about off front dates. Eight immoral A.. Ah So then Ashton calls this mom now this is like when someone calls their parents right before they get eliminated on project runway or option like acids are about to have a really bad day. So let's just humanize him a little bitch Halley Ashton back home so she's like Hoya Creation. Has it going home just to say hi okay. Is there an unconventional materials challenger. Not on project runway more Mama Cylinder Boat Show but you all making address data tree. Then why would you like to see all of your old daughter who you miss very much and just need. I heard to help you get through the next few days mom. I don't even have a four year. Old Daughter Tim Connelly's taking care of your baby. Mamas doesn't project runway. Hey we want to talk about. Do we want to talk about food. Saved Your Life WanNa talk about that. You lived in Nevada because of your drug addiction more. That never happened so She's like an he tells us his back story about. His parents divorced destroying him and she's like well how about that other lady. Then you're okay with her. He's kate will be kate mom. Maybe the hardy girl shoulder model. She's been fired since then. Ah So then courtney. Brian go on their day. And and Tannin sins goad have their break-up drink so first let's go to Brian Corny at a at a bar called. Dudek apostrophe deck did ECHO which also looks. Looks like it might only be about ten feet from the boat so they go in like a little car and they sit down and Brian's like do you want some champagne and she goes I am. I don't think they've champagne here wearing Thailand. He's like all what under saint paying what they have here. Doesn't it's an exist. So then she goes. I'M GONNA GRONYEA's Jato wait so you're saying that Thailand is this far flung one country they don't even have champagne one of the most popular like wines in the entire world. And then you're going to order this super super specific like variant of Negroni. Rony also. I'll have a number two super size with the site of having buster ranch plea vein vein I am. I would really like an old fashioned but like one that only uses bourbon that's locally sourced to A Certain County in Tennessee. Do you Have that okay this the champagne. Oh sorry forgot Thailand. WHO So? She's like I'm sorry a bit grumpy it was like well. Yeah look make trump to cheer you up here. I am and he's all disappointed and tells us she'll come around. Hopefully which are the puppy here. I know but then he doesn't help matters when he tries the order. He's like he's like. Can we get one to grow. Ni Now Negroni Smith now playing on how so she just size and he's like I don't know what to do. We can go back to the boat and relax. We can go tonight have actually talked about something you something you know do something better so yeah ask ask you just got what is she supposed to do. Just like go down on you because you took her out someplace. Yeah and then I should mention mentioned just to finish out this arc of the Negroni that it does arrive and she sips it is like is it the Negroni with the sparkling line. She's now a regular in agronomy and she's she's like mount by the way also mentioned that her version of this version has sparkling wine in it. I don't think a regular in the GRUNGY does but either way whatever it is has a sparkling wine in it. That's basically the same as champagne. Championship sparkling Wine Champagne region. So it's of that quality but when he said you WANNA get champagne just like why. Don't we get sparkling wine. You know what I'm saying. Yes ideally kind of upset. He's dumb but yeah you know I mean. She's almost makes me wonder if she ordered the grenade sloughing JATO JR and descried ride this ingredients. Just that way as a test to see if you'd be like oh well if they have sparkling wine we can just get that right like maybe he didn't pick up on. That was like I'm feeling the test. Yeah like you don't even champagne as champagne. I got obviously really we wrapped up in this whole Negroni situation. Well Tanner. Tanner pulled Simone aside psychic. Yes tanner and he's like. You know to be honest I feel like different mind waves. Let's just like I think we're on the same wind wave in these people that use the word Mont Way. Who Burns you say? What is it mind wave? And so she's like no. I'm pretty sure we're than say mine. I'll want to lead you on on. And she's like you're not leading me on N. G. When you said you wanted a fun. I knew what you were saying. I got it. He's like. Yeah so what I'm saying is I want to keep because will so I'm GonNa give you the keys to my apartment. That's what I'm saying. I was drunk. I don't remember. I was drunk when I said that. So I don't remember that but you know I don't WanNa hurt you. You didn't hurt me but I just WanNa have fun. She's like okay. That's great have fun and so she'd lasts to make him more comfortable and she's like it's fine line like it seriously. It's amazing how you such a cool chick. She is such a fuck boy you know he says yeah. Thanks for the thanks. Thanks for the approval. Tanner thanks for. Thanks for new into the cool check so then back on the day courtney's just like I wish I could be lying down like I'm just getting lower and lower on this chair away. Okay I'm only my head is on the chair and my buddy sort of over okay. No I'm on the floor. I'm on the floor down warning warning. I spent a lot of energy and time on this date. So what was it to go kart like what what what was it. That was not owed. You're not owed a good date. Although to be fair. She was clearly not in the mood to go on a day. And it's like so. Don't go on the date. I I feel like the producers made her go on this date and she was like really not in the mood to do it. Yeah but also like you're dating us our purpose and then you're like she's Osama puss. Let's you know they both. They both like had had like a many different ways to avoid the situation like she was not in the mood. She should have gone on the date. He's hitting someone who doesn't want to go on a date at five five o'clock and he should've like picked up on that and like you said it's getting us our purpose. She's looking representative. That's what's going to happen. Yeah she's actually don't think she's a sour plus. I think that she's just like you know. I think she just likes. She likes really likes things on her own terms. And I think that's the ongoing problem. I would not even be the on base I cannot even walk like Sao hot air remember. Her first episode was like beaching it when she had to the beach with tanner. He's like Jesus Christ. You always like this like yeah. She's not a therapist. She's a Ben. You're not a sour focus..
"brian corny" Discussed on The Readout Loud
"Robbins was San Diego which means she was in the room for the presentation. That we've been talking about Rebecca. What was it like among all the neuro-scientists analyst listening in on biogen's presentation so I think a key thing here was that everyone was listening to a really in the weeds presentation. We were talking charts scatter plots. That were really hard to interpret. Even if you've been scouring this data for weeks like many people in the room had so this was not sort of an easy clear presentation that had obvious takeaways it was really messy and I think the reaction in the room reflect that another thing that was interesting was that of the panel of experts that we're on stage the Renault voices of skepticism from the studies as well as big backers of the controversial idea that the key to treating. Alzheimer's is by clearing the brain of so called amyloid plaques so it was interesting that there was so much optimism on stage. I think didn't reflect the sentiment in the room and then the other thing that was notable was that there was no qna from the audience at the end of the presentation. So I think that all contributed to make the entire thing feel very positive and didn't leave a lot of room for skepticism so right after the presentation concluded Rebecca grabbed. A BUNCH OF EXPERTS IS C. Tad to ask them to give a hot take on the presentation. So what are those? Experts was Dr Jim Cubic. He was previously clinical head of Pfizer's neuroscience research group in Cambridge Mass. Pfizer. You'll remember killed it's neuroscience research program after failures Alzheimer's and other conditions Jim is now chief medical officer at a biotech called promise. Neurosciences someone has jim about biogen's presentation. He was very positive. He called the data exhilarating and set validated. The mechanism behind drugs meant work. Like at a cab does. But Jim also flagged a crucial caveat. The data set is limited in that the effect is limited so that points the need for a more sophisticated effective therapy. The truly is selected. Maybe even more specific for the toxic amyloid species which is a small lemurs in the future. We will have biomarkers that will really facilitate early clinical of elements that we can reach a go. No go decision point much earlier than face three and this has been the case where we seen this type of early drug becoming first vailable having limitations in terms of efficacy or safety. We've seen we've seen this CARDIOVASC- is and the next generation. Drugs are always superior in terms of efficacy and safety. I'm sure that that will be the case here. As the next generation of drugs are tested and become avail another expert I talked to was Dr Howard fill it. He's chief science officer at the Alzheimer's Drug Discovery Foundation. And he's historically been on the more optimistic side when it comes to drugs that work like out of cab but when I asked him what he made of the data. I was a bit surprised that he sounded fairly skeptical. Here's what he had to say all in all. I think that there was a signal both pharmacologically and clinically. But I think that they really need to do a third trial to confirm this and I. I don't know what FDA will do. But I expected that might be one of the outcomes under consideration. Rebecca also talked to Brian's Corny who is a biotech research analysts at the firm Robert Baird and he's been easily one of the most bearish analysts out there when it comes to educate him APPs prospects. He wrote a fairly blistering research in advance of the presentation that we're talking about saying that. Educate them Ed. Quote is not getting approved. Absent Dais X. Makia and that the data we've seen are convincing only to quote the most ardent goop subscribers so I asked S- corny. Does he feel any differently now? After hearing badges presentation I do not. I believe that the data was fairly consistent with what everyone's view on the data. Was I also ask? Oranje did anything. From Thursday's presentation change his thinking about the drugs. Prospects the fact that the panelists one after another sort of endorsed the positive effects of the emerge study a little bit surprised by that and certainly if the world has holds that view and I don't then I'll wind up being wrong and finally I asked him what the biggest question. He feels was unanswered today. I mean I think for me. It's how are the regulators? GonNa view the risk reward balance here. What I thought was new on the negative side and the presentation was I thought. There was a very very clear. Exposure related relationship in Aria. -demia cerebral micro hemorrhages. This is not a benign drug. And that's a fact so I think the problem is you're dealing with a drug. That's factually has safety shoes. Versus you know unclear if there's any efficacy benefit at all I personally don't believe that the signal is there that there isn't efficacy benefit but but I think it's indisputable that you can't say with any certainty that there is either so so it's the certainty of safety issue versus the uncertainty of his efficacy benefit. I think ultimately that's why I don't think it'll get approved now. We want to talk about a story that features one-eyed cheap poisonous plants biotech hype and patient. Empowerment Stats Eric. Bushman wrote a sweeping story about the hunt for new cancer medicines. One that bridges scientific history with the realities. The drug business and Eric joins us today to talk about Eric. Welcome back to the PODCAST. Thanks so much Damian Eric. Your story centers around a young woman named Kalian Sharon from East Boston. She is a rare disease called Gore. Lynn Syndrome. Explain to us what it's like for her to have that condition so Garland Syndrome has effects all over the body and those extend from skeletal abnormalities. To sort of unusual growths the most common are jaw cysts which often caused a lot of pain and also cause drainage into adjusted tract and also the uncontrollable proliferation of Basal Cell Carcinomas. Which are skin cancers? They're usually not thought of as especially serious because they can be removed fairly easily with surgery. But when you're getting hundreds upon hundreds and you're getting surgery after surgery after surgery. There's really an exhaustion of the scalpel that sets in. And so one of the issues that comes with always needing surgeries is that it can become a heart. Hold down a job when you need that much time off for medical care but also it's very disfiguring. So there's a topical drug currently being developed to treat Garland Syndrome by a company called farm. This drug has a fascinating history. Which you trace back to one eye cheap in the American West. Give us if you can eric. A brief version of where this drug came from the science first emerged pretty weird way. Where in the fifties? These Basque shepherds in Idaho noticed that sheep were giving birth to one eyed lambs. And they've actually called in some. Usda scientists one of whom actually camped with the sheep for three summers to figure out what was causing them. To give birth these deformed limbs and they pinpointed to plant which in turn was found to contain a chemical that plugged up the hedgehog pathway. The hedgehog pathway is really for most of the body only active when we're embryos and then it sort of put away under lock and key and in Garland Syndrome. Part of the issue is that that locking mechanism is broken. And so there's this uncontrolled growth that continues after. You're an embryo. And that causes the development of all these cancers and the thing that was causing deformities in lambs was that it was essentially plugging up these hedgehog genes and so these scientists thought. Oh great we have this molecule that can plug up this pathway. That's running wild in cancer patients. And then they thought. What if this works in every tumor under the sun so they started all these trials and pretty much? You name the cancer. They tried it. And there's a great scene that you depict in the story Eric of these drugs researchers going out into the field to Utah to literally dig up all of these plants to extract this chemical. Tell us about that. Many many drug companies started looking into Hedgehog. Pathway inhibitors and one of them was infinity which is based in Cambridge and they decided you know what let's go back to the roots literally and they went and got these plants that were causing these deformities in one eye cheap and they set up an enormous agricultural operation in Manta Sal National Forest in Utah. At first they started with picks and shovels but then as they started clinical trials they needed more and more roots and so they started lugging farm equipment up into the mountains and in the very short season that you have at nine thousand feet to dig. They dug up acres and acres and acres of cow cabbage or veteran California. Calm so picking up where we left off on the drug development angle. Eric mentioned how many cancers various drug companies tried hedgehog inhibitors against a lot of those trials ended in disappointment but not in Garland Syndrome where they've seen a lot of hope. So there's a moment in your story where killeen makes an ASS CAPPELLA farm. The company developing a drug for her condition. And that ask this if I agree to volunteer. Test the drug in your study. Will you've out to always make it affordable for those participants and I was curious. Is there a precedent for this kind of request? And why don't we see drug companies who are often desperate for patients to enrolling their studies for forever diseases? Why don't we see them making bargains like this more often? That's a really great question and I think a lot of drug companies including Palo farm think about this. Although I don't think they think about it in quite as extreme away as kaylene was proposing and so when she asked this question the Talafar CEO said well. Whether you get the placebo or not. Then you'll get a year of free medication after the trial. So if you've got the placebo you'll switch over. And then when she sort of pressed them with a friend of hers they said we might even extend that free drug all the way up to the moment when it hits the market and the friend said well. That's not actually enough. Because you know unlike most cancer treatments these cancers continue for the rest of your life. This is a chronic cancer treatment for Borland Syndrome. I think Pella farm and a lot of companies talk about copay assistance and all of these different programmes and kaylene still worries that even paying a portion of this could be unaffordable for her and other patients story. You do describe the you know the financial toxicity which is a term that people use the financial toxicity of her treatments where she was taking a drug to treat Gordon Syndrome in then you know for various reasons. Her Co pay went up dramatically and she couldn't afford and she had to go off that drug. Right yeah and in that case you know there was quite a bit of confusion. I think on her part which is understandable given the American health insurance system and I think her yearly deductible was going up and she ended up having to taking a different hedgehog inhibitor. This one a synthetic one from genetic and it may have been possible if she had pushed in slightly different ways to have kept taking that drug but I think the episode to her made her feel like. Wow these drugs are very very expensive. A single tiny thing can change in your insurance situation and suddenly your skin cancers pop back up so what ultimately happened to Kaitlin. On the one hand she is really excited about this clinical trial. Because when you take this kind of drug orally it has all sorts of terrible side effects as she put it. I had terrible muscle cramps and lost all my hair but it was the best time of my life when he was on these oral drugs. And so the idea of putting it on topically means that you might get the same effect but without losing your hair without the muscle cramps and the taste loss. So she's really excited about this trial and at the same time she feels like. Hey if I'm volunteering and giving you my body and my time I want you to make some kind of guarantee that I'll be able to afford the medication afterwards. And she felt like the drug company was not giving her as satisfying an answer or as well-thought-out an answer as she would have liked and so that really made her question whether she personally wanted to volunteer in this way which could mean that she might have to stop taking this drug and I think she sort of viewed that as a kind of quiet protests in a certain way without this question when i read an Eric Bushman special report. Where on earth did you dig up this story? This story actually emerged from different story. I went to the Garland Syndrome alliance conference with a different researcher thinking that I was writing a profile of that researcher I mentioned that researcher in the story. But she's not the center of it and I heard kaylene stand up and ask a question and I thought. Whoa WHAT AN AMAZING QUESTION. And coming from such a young person to such a powerful drug company founder. This is really interesting. I wonder how this is going to play out and I came back to Boston..
"brian corny" Discussed on CNBC's Fast Money
"Welcome come back to pass one and we've done earnings alert on a pair biotech names Amgen and Gilead both moving in the after our session. Let's get to Meg Meg Terrell with all the details neg. Hey Mel will a lot going on in biotech. We're going GONNA start with Gilead stock moving a little bit to the downside in the after hours down just a fraction. They're getting some Wall Street reaction right now. As the call is going on Michael Year jeffries calling this quote the Big Bang theory that he's referring to the big H._i._v.. Drug Big Tarbey which did beat estimates at one point one billion dollars in in the quarter saying solid results guidance raised driven by strong big Harvey Sales Bryansk over Baird says that looked Pretty Vanilla H._i._v.. Overall looked in line in about four billion dollars core cazenove J. P.. M. Says what everybody's thinking. which is that the new CEO Dan O'Day his commentary as it relates ongoing Manet? It's probably what folks are going to be focused on guys and that is what they are talking about on the call right now. Let's also talk about Amgen that stock is up quite a bit and not necessarily because of the beat that we saw them post in the second quarter. It's actually something that they're talking uh and their slides and on the call Wall Street Reaction Brian's Corny pointing out that in the quarter their drug new Lhasa declined faster than expected twenty four percent year over year. It's facing bio similar similar competition core Cazenove J. P. Morgan notes that end Berlin older drug was the biggest beat whereas its newer launches migraine Joke Amo Vegan. It's cholesterol degree path were mixed an omen refi pointing pointing out by far the biggest disclosure emden earnings is on the chaos inhibitor guys. This is a pipeline drug that he says is probably the most important drugs in their pipeline. It's for cancer and and in the company's slides they disclosed more responses than we've seen on this and other kinds of cancer so that's probably why the stock is up now back to you all right Max. Thank you meg tyrel guy where you on. That's exactly right because if you look I'm just new lasted. The.
"brian corny" Discussed on Bloomberg Radio New York
"Thank you so much. You're listening to Bloomberg BusinessWeek Jason Kelly alongside Carol Massar spoon. Berg radio. Freefall, and that's exactly what's happening to shares of Biogen today. Plummeting after the biotech giant said that it's experimental Alzheimer's drug was unlikely to be effective and that it was halting its research. It's another setback for drugmakers efforts overall to find a therapy for the Amit the company's stock as I mentioned Biogen down about a third in terms of its overall value. Let's get into the SEC Gunnar Watana. He is senior biotech analyst at Bloomberg intelligence. Our in house group of analysts he's here in our Bloomberg interactive brokers studio, Brian's corny also with us biotech and pharma, Alison Baird. He's joining us on the phone here in New York. I want to kick it off with you. So obviously a major disappointment kind of this. I walked into the studio said was this expected. Well, I think people are hoping for this situation to play out, but sadly histories repeated itself Carol, I mean, if you look back this is about six major product that's failed in phase three that targets the same mechanisms pretty far along. This is exactly it's interesting face one data that they got people excited about it. I really wish history taught us a lesson and here, but I mean it on its merits it did look like it had some sort of activity was it had side effects, which indicative as well. But. Did not align. So Brian come on in here. I mean, if you're an investor and you're looking at this. What what do you do at this point? Obviously, the answer that many people have is you sell the stock but longer term what does this mean? Yeah. So I mean for for for Biden specifically, I mean, I think people really have to start putting fresh eyes on it. I mean, this was a big hope for this management team. They leverage to the story really to a lot of people surprise is not really aggressively pursuing in a or b d that would potentially diversify away from a risk of failure. But you know, in essence elaborate in themselves even more to this beta amyloid hypothesis, so we wrote in our note today, we think. There's a chance for this to be oversold as people really struggle with confidence in management, but management credibility. What are the options for this team to even do here at this point to kind of reignite the story NS franchise, but it hasn't really been growing stable for now. But it's more competitive they've had a great asset in a drug called spin Roger for SMS, but that seemed to approaching the peak of its growth Herve as well. And there's certainly a lot of competition there. So right you maintain neutral reading on the stock. You know, we think it's going to be hard for investors to kind of find a floor that they're comfortable with. I do feel like there's two stories here. I feel like there's the one story about all these drugmakers trying to figure out a way how to treat Alzheimer's, and they've all been on a similar path in terms of a drug in its treatment and all of them so far have failed. So there's that story. And then there's also the story of okay? So what does this mean for Biogen going forward? Yeah. I mean to Brian's point as well. If you look at the catalyst horizon that in the next couple of years, but by doesn't really not a lot that could get me excited here. I mean, doesn't emit as Assad one acid last as maybe some stroke data that can come out of a Japanese trial, but the multiple sclerosis data that could come out in the middle of two thousand twenty but did this is kind of a kind of a bleak outlook in terms of really moving Catholic. So the company has some cash United has it ended two thousand eighteen but about two point five billion dollars in the Bank. Maybe take about a billion off for that for the for the reason the shelf night star. But now they need to start deploying the capital, and maybe maybe go on the road and set buying something here to really help them out. Well, I want to pick up on exactly that point Brian. What would they buy what's first sale at this point? And I think there's where there are going to be really critical of them, essentially, not doing a number of deals that would have made sense for companies that have had meaningful meaningful steps and valuation. So I mean, the names that are generally floated out there that make a lot of sense and sort of the CNN field neuro Cran NBA acts with recovers PT, which we also cover saints therapeutics. I just got an approval this week all of these companies had really significant valuation inflections over the last couple of years. They all make sense four by John. You know, at this point, the the numbers, actually, overshot what Biden would be capable of pain. Probably not in most of the instances. I think again, the issue is given how how management's performed over the last couple of years into this status at in a will investors, give them any credibility, even doing aquisition at all? Or is this a situation where you know, we're not going to see a resolution under this management. Team or even with by John as a free standing, and I just want to point out. Neuro current is up about six point two percent. Sage is up about three and a half percent. So the expectation is these could be some of the names, they both medicines apparently approved for neurological conditions that would kind of fit with Biogen's remaining core franchises, you mentioned in terms of MS. How quickly does Biogen have to do something? And is it done? This is just done. Yeah. I don't I don't expect to see anything that could save it at this point. I'd also suggest that the has some other assets in Alzheimer's as well. It's developing something with a company Eisai called D N two zero one. We went very convinced by the phase to data by that, you know, this this this whole amyloid hypothesis is really taking a blow here. So. The first company to pursue this strategy six around. I'd probably the six. Yeah. So so, yeah, maybe maybe there's some other modalities that you could probably target mean they have something in the pipeline that targets towel and a couple of others. But right now, I I would temporal my expectations on what on what the Alzheimer's pipelines going to how quickly do they do need to something. I mean. As as long as they don't have anything in the pipeline intensive catalysts. Not is not a good story and without getting too deep into the science, which I inevitably wouldn't understand. Why has this been such an elusive target? It's I've seen very complicated disease. Brian, but they're not alone in essentially failing here, right? Yeah. That's true. I mean, you know, we sorta cheekily tweeted some comments around how people keep coming back to the beta amyloid hypothesis even after every failure saying, oh, but this time it's different. It's different. I mean. I mean, frankly, it's because there's just not other ideas walking Alzheimer's, I think it's a black box disease. We don't understand it. Well, this has been the primary biological hypothesis. And despite all the clinical failures, I think the scientific community is just holding on for whatever they can identify that might play a role in the disease here. Unfortunately, it continues to be an area where investment apple just got sucked into a big void right seek. I have to think that investors. I mean, they want this to be true. Right. I mean, this is probably one of the highest profile most befuddling things that we're facing as a society. So many people have to deal with this. And I have to think there's some emotion tied up in this as well absolute Gammon, if you look at what d- projections for not just cost of treating patients with Alzheimer's who once you get to really isn't anything that that's out that modifies the disease, but it's not just that. It's also the the caregivers to the actual financial and economic impact on society.
"brian corny" Discussed on Super Station 101
"Through probably not it's hard is going to the flu that you and i experience when they beat the most until oh boy doubt don't get it you know i don't only to go kick we don't even it easier again something more threat the men and women that that that are seals and they do what they do it it's impressive i mean it is amazing stuff in at a really looking for talking to him and so we will talk to him coming up at twelve thirty that's brian corny looking forward to that on the program so we tears those last hour and so i got to bring it up to the the table now i wanna get your thoughts on this side you ever go to talk to day or target but there's always store i i used to love to shop there i don't anymore honestly ever since that whole transgender thing i i got old yeah yeah not sure which bathroom to use they're all that nastiest may not you person lambs a say in the we're bathroom weirdness yeah that led the calls stink for them well target apparently now once to they sell alcohol already but now they literally want to serve alcohol while you're at target so there thought process their applying for look or license at target stores so you can go when it would you're the cal pals and instead of having wind at homered a bar you can go win in order up a glass in shop so sit the shirt in a at tertiary a well i like that no this is scary big dave if you think your hand in your wife of credit card to go shopping that's gary enough talk about wrecking your bill of even higher when you include alcohol hey let's have our batchelor part either but i'm and you know what but that's going to be here so what is going to be you're right know that yeah that these people do that we can never bachelorette party and are batchelor forty at the same time there you imagine one and o roles company one and automotive than wanted this is not bad that's not a bad idea all the man can have a tool party.